Table 1.
Pharmaceutical targeting of hypoxia in PDAC.
| Target | Compound | Reference |
|---|---|---|
| Hypoxia | Inositol-trispyrophosphate (ITPP) | NCT02528526 [81,84] |
| Hypoxia-inducible factors (HIF) | XL888 | NCT03095781 |
| Tanespimycin | NCT00577889 [85] | |
| AUY922 | NCT01484860 [86] | |
| Acriflavine | [82] | |
| Hypoxia-activated prodrugs (HAP) | Evofosfamide | NCT02402062 [87], NCT00743379, NCT02047500 [83], NCT01381822, NCT03098160 [88] |
| Mitomycin | [89] | |
| Tirapazamine | [90] | |
| Apaziquone | [90] | |
| Metabolism | BPM31510 | NCT02650804 |
| NIR178 | NCT03207867 | |
| CPI444 | NCT03454451 | |
| Zoledronic acid | NCT00892242 | |
| Epacadostat | NCT03006302 | |
| Immunity | BMS813160 | NCT03184870, NCT03767582 |
| BL8040 | NCT02907099, NCT02826486 | |
| Olaptesed | NCT03168139 | |
| Plerixafor | NCT03168139 | |
| Chemokines/cytokines | Galunisertib | NCT02734160 [91] |
| Vactosertib | NCT02154646 | |
| AP21009 | NCT00844064 | |
| M7824 fusion protein | [92] | |
| NIS793 mAB | [28] | |
| Tocilizumab | NCT02767557 | |
| Siltuximab | NCT00841191 |